4/13
08:01 pm
espr
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference [Yahoo! Finance]
Medium
Report
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference [Yahoo! Finance]
4/2
04:56 pm
espr
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics [Yahoo! Finance]
Medium
Report
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics [Yahoo! Finance]
4/2
04:05 pm
espr
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
Medium
Report
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
4/2
04:00 pm
espr
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Medium
Report
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
3/31
08:00 am
espr
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
Low
Report
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
3/30
02:57 pm
espr
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins [Seeking Alpha]
Low
Report
Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins [Seeking Alpha]
3/30
08:00 am
espr
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
Medium
Report
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
3/20
08:22 am
espr
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines [Yahoo! Finance]
Low
Report
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines [Yahoo! Finance]
3/17
08:29 am
espr
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session [Yahoo! Finance]
Low
Report
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session [Yahoo! Finance]
3/17
08:00 am
espr
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
Neutral
Report
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
3/16
06:30 am
espr
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Medium
Report
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
3/15
08:16 pm
espr
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference [Yahoo! Finance]
Medium
Report
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference [Yahoo! Finance]
3/10
08:03 pm
espr
Esperion Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Esperion Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/10
03:12 pm
espr
Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
3/10
03:02 pm
espr
Esperion Therapeutics (ESPR) had its "buy" rating reaffirmed by HC Wainwright.
Low
Report
Esperion Therapeutics (ESPR) had its "buy" rating reaffirmed by HC Wainwright.
3/10
06:18 am
espr
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/10
06:00 am
espr
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
High
Report
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
3/5
11:36 am
espr
Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth [Yahoo! Finance]
Medium
Report
Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth [Yahoo! Finance]
3/5
07:14 am
espr
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease [Globe and Mail, The (Toronto, Canada)]
Medium
Report
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease [Globe and Mail, The (Toronto, Canada)]
3/4
05:43 am
espr
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements [Yahoo! Finance]
Low
Report
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements [Yahoo! Finance]
3/3
05:28 pm
espr
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript [Seeking Alpha]
Low
Report
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript [Seeking Alpha]
3/3
01:35 pm
espr
Esperion Therapeutics (ESPR) had its price target raised by Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Esperion Therapeutics (ESPR) had its price target raised by Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.
3/3
06:00 am
espr
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
High
Report
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
3/3
06:00 am
espr
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
High
Report
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
2/24
08:00 am
espr
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
Low
Report
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10